Cutting-Edge Cancer Treatment Technologies

Lukas Biomedical's memory T cell culture technology has received exclusive authorization from Japan's National Cancer Center. It has completed Phase III clinical trials with Japan's Ministry of Health, Labour and Welfare, and successfully conducted Phase IV clinical trials in South Korea. The technology has obtained drug approval and is now marketed in South Korea, with over 10,000 clinical treatment cases recorded in Japan and South Korea. It has been proven to be a stable and effective method of immunotherapy for cancer treatment.

說明

Globally Cutting-Edge Cancer Treatment Technologies

Lukas Biomedical has obtained exclusive authorization from Japan's Lymphotec Inc. to introduce the world's most advanced immunotherapy for cancer treatment, [LuLym-T (Autologous T Activated Lymphocytes; ATL)]. This technology was recognized by the U.S. Food and Drug Administration (FDA) with Orphan Drug Designation (ODD) for liver cancer and passed the U.S. IND review for Phase II clinical trials on February 12, 2021. Additionally, Lukas Biomedical is collaborating with Taipei Veterans General Hospital for Phase I and II clinical trials in head and neck cancer.

To ensure the safety and quality of our immunotherapy products, Lukas Biomedical adheres to Good Tissue Practice (GTP) standards. In 2019, we established a high-specification core laboratory for cellular products in Xizhi. In 2021, we received GTP certification as a cell processing unit (MOHW No. 1101662640). To safeguard liver cancer patients, we have specifically established a negative pressure laboratory for processing cell samples from hepatitis B and C patients.

Lukas Biomedical is composed of clinical doctors and top-tier researchers. In our internationally certified GTP cell culture laboratory, we have developed a platform for immunotherapy, creating cancer treatments that are safe, highly effective, and have minimal side effects. We have also implemented an integrated cancer care system, providing patients with comprehensive care to improve cancer survival rates, enhance the quality of life, and meet their healthcare needs.

The world's first T-cell cancer treatment technology to obtain drug approval

The immunotherapy introduced by Lukas Biomedical for cancer treatment has received drug approval and is publicly listed according to the official announcements and approved drug information in South Korea. Please refer to product number 6.